Shaoxing Marina Biotechnology

Shaoxing Marina Biotechnology is a Chinese biotechnology company focused on the development of RNA-based therapeutics using advanced delivery technologies. The company utilizes the DiLA2 (Dicetyl Phosphate-based Liposomal Amine) platform, originally developed by the US-based Marina Biotech, to create stable and effective delivery systems for small interfering RNA (siRNA). Its research and development efforts primarily target metabolic and genetic diseases, including hypercholesterolemia and amyloidosis. By leveraging its proprietary delivery platforms, the company aims to overcome the traditional challenges of nucleic acid stability and cellular uptake in RNA interference therapy.